Skip to NavigationSkip to content

Singulair gains dual asthma-hayfever indication

Published on 02/03/05 at 10:49am

Merck Sharpe & Dohme's blockbuster oral asthma treatment Singulair has received an expanded UK licence for the treatment of adult asthma with co-existing hayfever (seasonal allergic rhinitis).

Singulair can now be used to treat patients with both mild to moderate asthma and the relief of seasonal allergic rhinitis in adult asthma patients in whom the product is indicated.

MSD estimates that three to four million people in the UK suffer from both conditions, which are closely associated but tend to be managed separately.

Singulair received its first UK licence in 1998 and is currently one of MSD's US parent company Merck's four biggest-selling products.

Last year worldwide sales rose to $2.6 billion and Merck expects it to reach $3.2 billion in 2005. The company plans further new indications for Singulair against perennial allergic rhinitis, exercise-induced bronchospasm, acute asthma and respiratory syncytial viral bronchiolitis.


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches